

Myles A Ingram

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2252337/publications.pdf>

Version: 2024-02-01

11
papers

107
citations

1684188

5
h-index

1720034

7
g-index

11
all docs

11
docs citations

11
times ranked

171
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease Course and Outcomes of COVID-19 Among Hospitalized Patients With Gastrointestinal Manifestations. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1402-1409.e1.	4.4	28
2	Prevalence of <i>Clostridioides difficile</i> and Other Gastrointestinal Pathogens in Patients with COVID-19. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4398-4405.	2.3	27
3	Where Have All the Emergencies Gone? The Impact of the COVID-19 Pandemic on Obstetric and Gynecologic Procedures and Consults at a New York City Hospital. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 28, 1411-1419.e1.	0.6	24
4	Prediction of COVID-19 Social Distancing Adherence (SoDA) on the United States county-level. <i>Humanities and Social Sciences Communications</i> , 2021, 8, .	2.9	13
5	Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	1.3	10
6	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. <i>Cancer Reports</i> , 2022, 5, e1565.	1.4	4
7	Cost-effectiveness of universal screening for germline BRCA mutations in metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 536-536.	1.6	1
8	Cost-effectiveness analysis of platinum-based chemotherapy treatment options for germline BRCA-mutated locally advanced/borderline resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16246-e16246.	1.6	0
9	Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15517-e15517.	1.6	0
10	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16793-e16793.	1.6	0
11	Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16268-e16268.	1.6	0